Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) is pleased to announce that, on September 20, 2022, the marketing authorization for generics of Azilsartan tablets (specification: 20mg), developed and manufactured by the Group, has been obtained from the China National Medical Products Administration (“NMPA”) (國藥准字H20223680). The drug has been approved to treat hypertension.

Hong Kong, September 3, 2022, “the Healthcare and Biotech Road Map in Greater Bay Area” Symposium, sponsored by Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), was successfully held both virtually and physically at the center of Hong Kong Management Association. Lee’s Pharm was awarded with the certificate issued by Greater Bay Area Medical Professional Study Group for its steadfast support and generosity.

Hong Kong, August 12-14, 2022, the Jiangsu Psychiatry Conference 2022, co-organized by the Jiangsu Medical Association and its branch Psychiatric Association, was successfully held in Jiangsu, China. Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) kicked off a Satellite Meeting for Trittico®, the New “Excellent” Treatment for Depression, as to facilitate the intellectual interaction among the field of psychiatry.

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) has been recognized again as a “Caring Company” by The Hong Kong Council of Social Service (HKCSS). Lee’s Pharm attained Caring Company Award Logo for consecutive two years with good corporate citizenship recognition.

LOS ALTOS, Calif., July 18, 2022 -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that the Company has entered into an agreement granting exclusive rights to develop, market and commercialize Renazorb® (lanthanum dioxycarbonate) to Lee's Pharmaceutical (HK) Limited, a wholly-owned subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm”)(SEHK: 950), in Mainland China, Hong Kong, and certain other Asian markets. Renazorb is Unicycive’s novel phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients.

The 2022 China Medical and Health Industry Symbiosis Conference, organized by Menet, the healthcare information platform was held in Huzhou, Zhejiang Province, China from 12 to 15 July, 2022. The lists of “Top 100 ranking of Chinese Pharmaceutical Industry”, “Top Brand of Chinese Pharmaceuticals” and “2022 Most Valuable Product in Partnership for Drug Store Chain in China” were released. The in-licensed product of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), Ferplex® was elected as “2022 Most Valuable Product in Partnership for Drug Store Chain in China”.

Hong Kong, July 12, 2022, Menet, the healthcare information platform announced the annual ranking series of Chinese Pharmaceutical Industry in 2021. Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) continued to hold the award of “Top 100 Chinese Chemical Pharmaceutical Companies” in the year 2021. The Group has been the winner of this award for three consecutive years since 2019.

TOKYO & HONG KONG, June 30, 2022 ‐ Lee’s Pharmaceutical Holdings Limited (SEHK stock code: 0950, Headquarters: Hongkong, Executive Managing Director: Lee lalertsuphakun Wanee, hereinafter “Lee’s Pharm”) and Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) jointly announced today that Solasia and Lee’s Pharm have entered into a business transfer agreement for the rights of promoting, distributing and selling of Sancuso® and episil® in Beijing, Shanghai and Guangzhou in the People’s Republic of China.

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) is pleased to announce that, on 31 May 2022, the Drug Registration Certificate for in-licensed product Teglutik® (Riluzole Oral Suspension) has been obtained from the China National Medical Products Administration (NMPA). Teglutik® has been approved to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (“ALS”).

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) is pleased to announce that, the Drug Registration Certificate for in-licensed product Natulan® (Procarbazine Capsules) has been obtained from the China National Medical Products Administration (“NMPA”). Natulan® has been approved for use in combination with other anticancer drugs to treat Hodgkin’s Lymphoma (“HL”).

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”) announced that, the registration of in-licensed product “Nitric Oxide for Inhalation” (INOmax®) was approved for commercialization by China National Medical Products Administration (NMPA). INOmax®, the first medicinal gas product approved in China, is an inhaled nitric oxide pharmaceutical for treating term and near-term neonates (>34weeks) with hypoxic respiratory failure (HRF) associated with pulmonary hypertension (PPHN). It is indicated to improve oxygenation and reduce the need for extra-corporeal membrane oxygenation (ECMO) of patients.

Hong Kong, March 22, 2022, the Retail Sales Department of the Group Commercial Operations Centre, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”) signed the Comprehensive Strategic Cooperation Agreement with Guangdong Rongtai Pharmaceutical Company Limited (“Rongtai Pharmaceutical”).